Soft Tissue Sarcoma
Pipeline by Development Stage
Drug Modality Breakdown
Soft Tissue Sarcoma is a <$1M market with minimal commercial activity and heavy reliance on a single branded alkylating agent approaching loss of exclusivity.
Key Trends
- Dominant market leader (YONDELIS) facing patent cliff in July 2028
- Early-stage pipeline with 163 trials heavily concentrated in Phase 1-2, indicating exploratory R&D activity
- Sparse Part D spending suggests limited reimbursement penetration or small eligible patient population
Career Verdict
Soft Tissue Sarcoma is a niche, low-revenue oncology area best suited for specialists willing to accept limited commercial scale in exchange for focused R&D or medical affairs work; broad pharma career growth here is constrained.
AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data
Market Leaders
| # | Product | Company | Revenue | Share | Stage | Trend | LOE |
|---|---|---|---|---|---|---|---|
| 1 | YONDELIS (trabectedin) | Johnson & Johnson | $578K | 100% | LOE_APPROACHING | Declining | 2.2yr |
Drug Class Breakdown
stable within class; declining overall due to patent cliff
Career Outlook
DecliningSoft Tissue Sarcoma is a specialist oncology niche with minimal commercial upside and a shrinking revenue base post-2028 patent cliff. The market is too small to sustain independent career growth in brand management or sales, but offers meaningful opportunities for clinical development, medical affairs, and translational research professionals willing to work in a rare-disease context. Job mobility into broader oncology is feasible but requires cross-indication experience.
Breaking In
Enter STS only if you are committed to rare-disease or translational oncology work; the market size and patent cliff limit long-term commercial prospects, so prioritize building deep clinical/scientific expertise over sales skills.
For Experienced Professionals
If you are an established commercial or clinical leader, avoid STS as your primary specialization; instead, use it as a niche rotation within a broader oncology portfolio to develop rare-disease and early-stage pipeline management capabilities.
In-Demand Skills
Best For
Hiring Landscape
Total hiring across pharma broadly is 6,157 jobs; however, only a small fraction is directly attributable to STS given the narrow product portfolio and $578K market. Johnson & Johnson dominates STS-relevant hiring (1,462 jobs) but the majority are across broader oncology and non-oncology roles. Commercial roles (1,210 jobs, avg $215K) and Manufacturing (488 jobs, avg $232K) lead hiring, reflecting mature-stage drug management rather than growth.
By Department
Hiring is concentrated in commercial and manufacturing for mature-stage drug management; R&D and Clinical Operations roles command $224K–$307K but are limited in count, making specialization risky without broader oncology experience.
On Market (2)
Approved therapies currently available
Competitive Landscape
35 companies ranked by most advanced pipeline stage
+5 more companies
Trial Timeline
Clinical trial activity over time
Showing 15 of 50 trials with date data
Clinical Trials (50)
Total enrollment: 5,884 patients across 50 trials
Study of ADI-PEG 20 or Placebo Plus Gem and Doc in Previously Treated Subjects With Leiomyosarcoma (ARGSARC)
A Clinical Trial to Evaluate the Efficacy and Safety of Anotinib Hydrochloride Capsule Combined With Epirubicin Hydrochloride Versus Placebo Combined With Epirubicin Hydrochloride in First-line Treatment of Advanced Soft Tissue Sarcoma
tTF-NGR Randomized Study - STS
A Study Comparing the Efficacy of L19TNF+Doxorubicin vs Doxorubicin Alone as First-line Therapy in Patients With Advanced or Metastatic Soft Tissue Sarcoma
A Study of Doxorubicin Plus Olaratumab (LY3012207) in Participants With Advanced or Metastatic Soft Tissue Sarcoma
Study of Palifosfamide-tris in Combination With Carboplatin and Etoposide in Chemotherapy Naïve Patients With Extensive-Stage Small Cell Lung Cancer (The MATISSE Study)
A Trial of TH-302 in Combination With Doxorubicin Versus Doxorubicin Alone to Treat Patients With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma
Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Dacarbazine in Subjects With Soft Tissue Sarcoma
Study of Palifosfamide-tris in Combination With Doxorubicin in Patients With Front-line Metastatic Soft Tissue Sarcoma
Trial for Localised High-risk Rhabdomyosarcoma and Rhabdomyosarcoma-like Soft Tissue Sarcoma
Study of Anlotinib in Patients With Soft Tissue Sarcoma（STS）(ALTER0203)
SATURN-STS: Phase II Study of Neoadjuvant Atezolizumab With Doxorubicin, Concurrent Atezolizumab With Pre-operative Radiation Therapy and Adjuvant Atezolizumab in Patients With High-risk Surgically Resectable Extremity and Truncal Soft Tissue Sarcoma
TQB2916 Injection Combined With Chemotherapy or Penpulimab Injection in the Treatment of Solid Tumors
A Clinical Study to Investigate the Efficacy of Intratumoral Tigilanol Tiglate in Soft Tissue Sarcoma
Chiauranib for Advanced or Unresectable Soft Tissue Sarcoma(STS)
Phase II Study of TAEST16001 in Soft Tissue Sarcoma
Camrelizumab Plus Doxorubicin for the First Line Treatment of Adcanced Soft Tissue Sarcoma
Efficacy and Safety of L19TNF in Previously Treated Patients with Advanced Stage or Metastatic Soft-tissue Sarcoma
Anlotinib Maintenance Treatment for Advanced Soft Tissue Sarcoma
LTX-315 and Adoptive T-cell Therapy in Advanced Soft Tissue Sarcoma (ATLAS-IT-04)
SARC028: A Phase II Study of the Anti-PD1 Antibody Pembrolizumab (MK-3475) in Patients With Advanced Sarcomas
A Japanese Trial of TH-302 in Subjects With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma
Adenoviral Vector Monotherapy or Combination With Chemotherapy in Subjects With Recurrent/Metastatic Breast Cancer.
Palifosfamide in Treating Patients With Recurrent Germ Cell Tumors
An Open-label, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Previously Treated Subjects With Advanced or Metastatic Soft Tissue Sarcoma (Study E7389-J081-217)
A Study of Axitinib in Patients With Advanced Angiosarcoma and Other Soft Tissue Sarcomas
Study on Efficacy and Tolerability of Vorinostat in Patients With Advanced, Metastatic Soft Tissue Sarcoma (STS)
A Study of Palifosfamide Tris Plus Doxorubicin Versus Doxorubicin in Unresectable or Metastatic Soft-tissue Sarcoma
Efficacy and Safety Study of CC-4047 (Pomalidomide) to Treat Advanced Soft Tissue Sarcoma
Safety and Efficacy Study of Glufosfamide in Previously Treated Advanced Soft Tissue Sarcoma
E7389 Administered as an IV Bolus Infusion Day 1 and Day 8 Every 3 Weeks in Pre-Treated Patients With Advanced and/or Metastatic Soft Tissue Sarcoma
Neoadjuvant and Adjuvant Chemotherapy in High-risk Soft Tissue Sarcoma
A Study of LVGN6051 Combined with Anlotinib in Patient with Soft Tissue Sarcoma
Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma
Pembrolizumab and Radiation Therapy in Treating Patients With Intermediate or High-Grade Soft Tissue Sarcoma
A Study of Olaratumab (LY3012207) in Participants With Advanced Soft Tissue Sarcoma
Trial of Neoadjuvant Conformal Radiotherapy Plus Sorafenib for Patients With Soft Tissue Sarcoma of the Extremity and Body Wall
Sunitinib and Radiation in Patients With Resectable Soft-tissue Sarcoma
Dose-Escalation Study of TH-302 in Combination With Doxorubicin to Treat Patients With Advanced Soft Tissue Sarcoma
89Zr-olaratumab Dosimetry in Participants With Soft Tissue Sarcoma
Study of Autologous Tumor-Infiltrating Lymphocytes in Pediatric, Adolescent, and Young Adult Participants
Neoadjuvant ADI-PEG 20 + Ifosfamide + Radiotherapy in Soft Tissue Sarcoma
Study Evaluating the Safety and Efficacy of MEDI5752 in Combination With Stereotactic Radiotherapy in Patients With Metastatic Sarcoma
A Study of HFB301001 in Adult Patients With Advanced Solid Tumors
TAEST16001 in the Treatment of Soft Tissue Sarcoma
Dose Finding Study of L19TNF and Doxorubicin in Patients With STS
A Safety Study of SGN-CD47M in Patients With Solid Tumors
A Study of Olaratumab (LY3012207), Doxorubicin, and Ifosfamide in Participants With Advanced or Metastatic Soft Tissue Sarcoma
A Study of Olaratumab (LY3012207) Plus Pembrolizumab in Participants With Advanced or Metastatic Soft Tissue Sarcoma
Study of Selinexor and Doxorubicin in Advanced Soft Tissue Sarcomas
Related Jobs in Oncology
Regional Medical Leader(MSL) (Oncology/Immuno-Oncology/GI)
Senior Oncology Sales Specialist
Senior Oncology Sales Specialist
Senior Oncology Sales Specialist
Senior Oncology Sales Specialist
Senior Oncology Sales Specialist
Phase Legend
Key Insights
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.